摘要
心力衰竭(heart failure,HF)是各种心脏疾病发展的晚期阶段,患病率和病死率始终居高不下,HF患者的诊治工作一直是临床研究的重点。传统生物标志物B型利钠肽(B-type natriuretic peptide,BNP)和N末端B型利钠肽(N-terminal pro-BNP,NT-proBNP)虽已广泛应用于临床,却易受其他因素影响,限制了其应用,因此寻找其他有效生物标志物是未来的发展方向。炎症反应在HF发生、发展过程中起关键作用,此过程伴随着循环中一系列炎性生物标志物的变化,这些生物标志物可作为HF发生风险及不良预后的预测因子,与传统生物标志物联合应用有助于提高HF患者临床诊断和病情严重程度评估的准确性。
Heart failure(HF)is a serious condition that various heart diseases develop in their advanced stages,and the morbidity and case fatality remain high.The diagnosis and treatment of patients with HF have always been the focus of clinical research.Although the traditional biomarkers B-type natriuretic peptide(BNP)and N-terminal pro-B-type natriuretic peptide(NT-proBNP)have been widely used in clinic,they are easily affected by other factors,which limits their application.Therefore,looking for other effective biomarkers is the future direction.Inflammatory response plays a key role in the occurrence and development of HF,and is accompanied by a series of changes in circulating inflammatory biomarkers.These biomarkers can be used as predictors of the risk and poor prognosis in HF,and their combined application with traditional biomarkers can help improve the accuracy of clinical diagnosis and severity assessment of patients with HF.
作者
满婧(综述)
赵德超(审校)
MAN Jing;ZHAO Dechao(Department of Cardiology,First Affiliated Hospital of Harbin Medical University,Harbin 150001,China)
出处
《临床与病理杂志》
CAS
2022年第2期455-461,共7页
Journal of Clinical and Pathological Research
关键词
心力衰竭
炎症
生物标志物
heart failure
inflammation
biomarkers
